Showing results (401-410 of 2,525) with videos related to

Sort By:
Pageof 253
BMC Endocrine Disorders|June 11, 2020
Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic reviewJuan Gómez-Izquierdo, Kristian B Filion, Jean-Franҫois Boivin, et al.
BMC Endocrine Disorders|June 11, 2020
Correction to: High normal TSH is associated with lower mannan-binding lectin in women of childbearing ageMalgorzata Karbownik-Lewinska, Jan Stepniak, Magdalena Marcinkowska, et al.
BMC Endocrine Disorders|June 12, 2020
Evaluation of risk factors for insulin resistance: a cross sectional study among employees at a private university in LebanonMyriam Fahed, Maya G Abou Jaoudeh, Samar Merhi, et al.
BMC Endocrine Disorders|May 1, 2021
Investigating the prevalence of primary thyroid dysfunction in obese and overweight individuals: Tehran thyroid studyMahdi Mahdavi, Atieh Amouzegar, Ladan Mehran, et al.
BMC Endocrine Disorders|June 5, 2020
Large mid-upper arm circumference is associated with metabolic syndrome in middle-aged and elderly individuals: a community-based studyJie Shi, Zhen Yang, Yixin Niu, et al.
BMC Endocrine Disorders|May 23, 2021
A case report of pseudohypoaldosteronism type II with a homozygous KLHL3 variant accompanied by hyperthyroidismRui Zhang, Simin Zhang, Yingying Luo, et al.
BMC Endocrine Disorders|May 23, 2021
Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratificationSachiko Ohde, Kensuke Moriwaki, Osamu Takahashi
BMC Endocrine Disorders|August 4, 2021
Investigation of the levels of circulating miR-29a, miR-122, sestrin 2 and inflammatory markers in obese children with/without type 2 diabetes: a case control studyKhalid M Mohany, Osamah Al Rugaie, Osama Al-Wutayd, et al.
BMC Endocrine Disorders|August 5, 2021
Endogenous estrogen exposure and chronic kidney disease; a 15-year prospective cohort studyMaryam Farahmand, Fahimeh Ramezani Tehrani, Davood Khalili, et al.
BMC Endocrine Disorders|July 14, 2025
Risk factors and outcomes of thyroid immune-related adverse events following PD-1/PD-L1 inhibitors treatment in a large tertiary Chinese centerWenwen Gong, Erhan Zheng, Minchao Liu, et al.
Pageof 253